Drug Approval | June 06, 2022
FDA publishes ANP’s polymeric drug excipient DMF
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
The centre works with active pharmaceutical ingredients (APIs) and can utilize innovative concepts with model APIs
Lonza to expand inhalation services by adding capabilities at its Tampa (US) site as part of its continued focus on providing bioavailability enhancement series for global customers
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
The facility is among 12 centres established worldwide, and the first in Asia
Under the terms of the agreement, Bachem will provide the appropriate engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology
To meet the growing global demand for respiratory active pharmaceutical ingredients (APIs), Inke is to invest €9 million into its production plant to reinforce focus on inhalation micronised APIs
The expansion positions Cambrex with the largest and most advanced API facility in the United States
Subscribe To Our Newsletter & Stay Updated
